Question 1 of 6: Feasibility Assessment of an Off-the-Shelf Bioengineered Liver

Question 1: Feasibility Assessment of an Off-the-Shelf Bioengineered Liver (20 marks)

Question text not reproduced: the examination questions are © Engineers and Geoscientists BC. Open the official past paper (linked at the top of this page) to read the question, then follow the worked solution below.

(a) Major Technical Areas in Engineering an Off-the-Shelf Bioengineered Liver

An “off the shelf” whole-organ liver replacement, starting from embryonic stem cells (ESCs) alone, requires work across at least seven linked technical areas, and the single line of technical information given (cell source only) is nowhere near sufficient to validate the claim. Cell-source biology and differentiation comes first: ESCs must be reproducibly directed down a hepatocyte lineage at high purity and functional maturity (mature hepatocyte-specific metabolic and detoxification enzyme expression, e.g. cytochrome P450 activity, urea-cycle function, albumin secretion), and, for a functional organ, also into the supporting non-parenchymal cell types — liver sinusoidal endothelial cells, Kupffer cells, stellate cells, and bile-duct (cholangiocyte) epithelium — because any residual undifferentiated pluripotent cells carry a real tumorigenic (teratoma) risk once implanted. Scaffold/matrix engineering provides the 3-D architecture the cells are seeded onto or into — either a decellularized native liver extracellular matrix (which uniquely retains the organ's dual-inlet vascular tree and the lobular/zonal architecture on which liver metabolic function depends) or a synthetic/hybrid biomaterial scaffold engineered to support the liver's characteristic metabolic zonation (periportal vs. pericentral hepatocyte function differs along the sinusoid). Vascularization and perfusion engineering is an especially hard problem for the liver specifically, because the organ requires a functioning dual blood supply (portal vein providing ~75% of flow, hepatic artery the remainder) delivered through an engineered sinusoidal microvascular network; diffusion alone only sustains viable tissue to roughly 100–200 µm from a capillary, so a functioning liver of clinically useful size needs this perfusable network established before or during cell seeding, not just a bulk scaffold. Biliary/excretory system engineering is a further liver-specific requirement with no direct heart or vascular-graft analogue: an engineered bile-duct network must collect hepatocyte-secreted bile and route it to an outflow, or the construct will develop cholestatic injury. Bioreactor and manufacturing scale-up is needed to reproducibly grow a viable, GMP-quality whole organ (very different from a benchtop hepatocyte-spheroid proof-of-concept). Immunogenicity management is essential because ESC-derived tissue is allogeneic (or, from a third-party donor line, fully foreign) to the eventual recipient, so either lifelong immunosuppression, genetic immune-evasion engineering of the donor cell line, or a patient-matched/induced-pluripotent-cell approach must be part of the technology. Finally, regulatory and long-term preclinical validation (large-animal survival studies, a defined combination-product regulatory pathway, and an ISO 10993/quality-system framework) closes the loop from laboratory demonstration to an actual “off the shelf” clinical product.

(b) Criteria for Assessing the Design's “Success”

Given only “cell source: embryonic stem cells,” the economic team should be told that success has to be judged against criteria spanning function, durability, safety, and manufacturability — not against the marketing claim alone. Functional criteria: demonstrated adequate liver-specific metabolic function (ammonia clearance/urea synthesis, drug/xenobiotic metabolism via cytochrome P450 activity, albumin and clotting-factor synthesis, bilirubin conjugation) in a physiologically relevant large-animal orthotopic transplant model, sustained over a clinically meaningful period, not just a benchtop hepatocyte-culture assay. Structural/durability criteria: long-term mechanical and structural integrity of the scaffold and tissue, maintained microvascular (sinusoidal) perfusion over time, and functioning bile drainage without cholestasis. Biocompatibility and safety criteria: no teratoma formation from residual undifferentiated ESCs, no clinically significant rejection response, and no thromboembolic events from any blood-contacting engineered vascular surface (directly analogous to the vascular-graft haemocompatibility problem of Question 2). Manufacturability/reproducibility criteria: consistent product quality and functional performance across independently manufactured units, since a device claimed to be “off the shelf” implies a reproducible manufacturing process, not a one-off laboratory success. Regulatory/translational criteria: a credible, de-risked path through the applicable combination-product regulatory framework with a completed preclinical safety/efficacy package. A firm that can show only isolated hepatocyte metabolic activity in a dish, with no vascularization, biliary drainage, immunogenicity, or large-animal durability data, has not demonstrated a viable “liver” by any of these criteria, regardless of how the technology is described in a stock-price-oriented communication.

Practical Application

A due-diligence checklist built from these criteria — e.g., “hepatocyte purity and residual-pluripotency assay: UNKNOWN, HIGH risk; engineered sinusoidal perfusion demonstrated in vivo: UNKNOWN, HIGH risk; functioning bile drainage: UNKNOWN, HIGH risk; large-animal survival >90 days: UNKNOWN, HIGH risk” — converts the vague marketing message into a concrete, evidence-based risk register the economic team can act on.